EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Date: March 20, 2025
| Eupraxia Pharmaceuticals Inc. | |
|---|---|
| By: | /s/ James A. Helliwell |
| Name: James A. Helliwell | |
| Title: Chief Executive Officer | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.